Parkinson's disease (PD) is characterized mainly by motor dysfunctions due to the
progressive loss of dopaminergic neurons. However, PD patients experience a multitude of …

Navigate PD was an educational program established to supplement existing guidelines
and provide recommendations on the management of Parkinson's disease (PD) refractory to …

Motor complications in Parkinson's disease (PD) result from the short half-life and irregular
plasma fluctuations of oral levodopa. When strategies of providing more continuous …

Apomorphine is often considered an archetypal dopamine agonist used in the treatment of
Parkinson's disease (PD). However, it can be clearly differentiated from most other …

To report on OPTIPUMP, a cohort study, investigating the impact in real-life clinical settings
of continuous subcutaneous apomorphine infusion (CSAI) on the quality of life (HRQoL) of …

Background: The clinical condition of advanced Parkinson's disease (PD) patients is often
complicated by motor fluctuations and dyskinesias which are difficult to control with available …

Depressive disorders as well as depressive symptoms are common in Parkinson's disease
(PD) and an important factor affecting quality of life. Treatment of depressive symptoms not …

In the advanced stages of Parkinson's disease (PD), patients frequently experience
disabling motor complications. Treatment options include deep brain stimulation (DBS) …

The present paper consists of a comprehensive review of the literature on apomorphine
pharmacological properties and its usefulness in Parkinson's disease (PD). The chemistry …

Increasing interest has been addressed toward the introduction of new therapeutic
approaches to obtaining continuous dopaminergic stimulation (CDS). The goal of this …